Meridian Medical Technologies

SIGA Reports Financial Results for Three Months Ended March 31, 2024

Retrieved on: 
Dienstag, Mai 7, 2024
TPOXX, Conference, Smallpox, Tax, Meridian Medical Technologies, Vaccinia, Cowpox, Government, Vaccine

Effective June 1, 2024, SIGA will drive international promotion activities for oral TPOXX® while maintaining its contractual relationship with Meridian to maintain continuity for key customer relationships.

Key Points: 
  • Effective June 1, 2024, SIGA will drive international promotion activities for oral TPOXX® while maintaining its contractual relationship with Meridian to maintain continuity for key customer relationships.
  • In first-quarter 2024, SIGA delivered approximately $24 million of oral TPOXX to a diverse mix of customers.
  • On March 12, 2024, SIGA’s Board of Directors declared a special cash dividend of $0.60 per share, which was paid on April 11, 2024.
  • SIGA will host a conference call and webcast to provide a business update today, Tuesday, May 7, 2024, at 4:30 P.M.

Meridian Medical Technologies, Kindeva Drug Delivery’s Global Health Security Division, Awarded Contract to Supply DuoDote®

Retrieved on: 
Dienstag, November 14, 2023
Medical Devices, Other Defense, Medical Supplies, Contracts, Chemicals, Plastics, Manufacturing, Health, Pharmaceutical, Defense, Health technology, Head, ASPR, Emergency, Meridian Medical Technologies, FDA, Infection, Antidote, Kindeva, Human services, Pralidoxime, Atropine, Administration, Hospital, CBRN, Meridian

Meridian Medical Technologies, LLC (Meridian), a division of Kindeva Drug Delivery (Kindeva), has been awarded a $9.9M contract to supply DuoDote® to the Administration for Strategic Preparedness and Response (ASPR) within the United States (U.S.) Department of Health and Human Services.

Key Points: 
  • Meridian Medical Technologies, LLC (Meridian), a division of Kindeva Drug Delivery (Kindeva), has been awarded a $9.9M contract to supply DuoDote® to the Administration for Strategic Preparedness and Response (ASPR) within the United States (U.S.) Department of Health and Human Services.
  • Meridian is a globally leading health security and chemical, biological, radiological, and nuclear (CBRN) medical countermeasure provider.
  • Meridian supplies DuoDote® to U.S. and allied ministries of health and defense, as well as hospitals and civilian first responder agencies.
  • “Meridian has a decades long history of providing medical countermeasures to military and public health agencies and civilian responders globally.

SIGA Announces Creation of Joint Procurement Mechanism by European Commission with Anticipated Initial Orders of Approximately $18 Million for Oral TPOXX® (Tecovirimat) by Participating Countries

Retrieved on: 
Montag, Oktober 23, 2023
European Commission, TPOXX, SIGA Technologies, Health Emergency Preparedness and Response Authority, Meridian Medical Technologies, Civil service commission, European Free Trade Association, EFTA, European, Smallpox, Vaccine, EU

Based on commitments from EU member countries, it is currently anticipated that $18 million in approximate value of oral TPOXX will be initially ordered by EU countries under this mechanism within the next 60 days.

Key Points: 
  • Based on commitments from EU member countries, it is currently anticipated that $18 million in approximate value of oral TPOXX will be initially ordered by EU countries under this mechanism within the next 60 days.
  • Orders through the joint procurement mechanism will result in country-level procurement of oral TPOXX.
  • Separately, as announced in September of 2022, the European Commission procured oral TPOXX through the funding of a direct purchase.
  • “With the creation of a joint procurement mechanism, there are now multiple paths in Europe for efficient procurement of oral TPOXX,” said Phil Gomez, CEO of SIGA.

Meridian Medical Technologies, LLC, and the European Commission’s DG HERA Sign Agreement for 13 Countries From the EEA to Purchase Tecovirimat SIGA

Retrieved on: 
Montag, Oktober 23, 2023
Other Defense, Infectious Diseases, Contracts, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Defense, European Economic Area, Vaccinia, Medication, SIGA Technologies, Cowpox, Health Emergency Preparedness and Response Authority, Mpox, Meridian Medical Technologies, European Medicines Agency, JPA, MHRA, European, HERA, Smallpox, Tecovirimat, EMA, Joint, Gross metropolitan product, Medicines and Healthcare products Regulatory Agency, Health technology, Patient, Vaccine, Nursing, Meridian, EEA, EU

Meridian Medical Technologies, LLC (Meridian), a global health security leader in providing medical countermeasures, today announced a framework contract under the Joint Procurement Agreement (JPA) was signed between Meridian and the European Commission’s Directorates-General (DG) HERA (Health Emergency Preparedness and Response Authority).

Key Points: 
  • Meridian Medical Technologies, LLC (Meridian), a global health security leader in providing medical countermeasures, today announced a framework contract under the Joint Procurement Agreement (JPA) was signed between Meridian and the European Commission’s Directorates-General (DG) HERA (Health Emergency Preparedness and Response Authority).
  • As part of a promotional licensing agreement, Meridian is a global commercialization partner for SIGA Technologies, Inc. (NASDAQ: SIGA), which is the marketing authorization holder and manufacturer of Tecovirimat SIGA.
  • Under the JPA, 13 participating countries from the European Economic Area (EEA) (Contracting Parties) can now efficiently purchase Tecovirimat SIGA, which has been approved by the European Medicines Agency (EMA) and Medicines and Healthcare Products Regulatory Agency (MHRA) for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications.
  • This agreement will result in country-level procurement of oral Tecovirimat SIGA and serve as a template for future procurement opportunities.

Meridian Medical Technologies, a Kindeva Drug Delivery Company, Investing $100+ Million in Bridgeton, Missouri, Expansion

Retrieved on: 
Dienstag, April 11, 2023
Science, Biotechnology, Research, Pharmaceutical, Health, Medical Devices, Chemicals, Plastics, Manufacturing, Georgia Department of Economic Development, The Missourians, EnergySolutions, Health technology, Greater St. Louis, Quality of life, Volksgemeinschaft, Multimedia, Meridian Medical Technologies, History, CDMO, Community, Economic development, Growth, Syringe, Renewable energy, Nursing, Meridian, St. Louis

View the full release here: https://www.businesswire.com/news/home/20230411005159/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230411005159/en/
    Meridian Medical Technologies, a Kindeva Drug Delivery Company, is converting this newly purchased facility in Bridgeton, Missouri, into a 155,000-square-foot state-of-the-art aseptic fill-finish site.
  • (Photo: Business Wire)
    “We’re proud to have a leading, high-tech manufacturer like Meridian Medical Technologies expanding in St. Louis,” said Gov.
  • Now with Kindeva, the combined company has a broader range of drug delivery capabilities that this Bridgeton facility investment will help support worldwide.
  • We look forward to working with them.”
    “The expansion of Meridian Medical Technologies is a significant step forward for St. Louis,” said County Councilwoman Kelli Dunaway.